Gastric Ulcer
Conditions
Interventions
To administer oral dose of famotidine (10mgg) and monitor gastric pH for 24 hours
To administer oral dose of famotidine (20mg) and monitor gastric pH for 24 hours
Sponsors
Medical Co. LTA Hakata Clinic
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1, Healthy Japanese male subjects who provide signed written informed consent. 2, Subjects between 20 and 40 (inclusive) year of age at the time of consent. 3, Subjects with BMI <=18.5 and >25.0 at the time of screening. 4, Subjects judged as adequate for this study by study physician.
Exclusion criteria
Exclusion criteria: 1, Subjects with present illness which requires treatment. 2, Subjects with past medical history which was considered not adequate for this study. 3, Subjects with past history of drug allergy. 4, Subjects who took prescribed medicine and/or OTC drug 1 week prior to admission of period 1. 5. Subjects who donated and/or withdrawn whole blood more than 400mL within 12 weeks, 200mL within 4 weeks, and/or blood component within 2 weeks prior to admission of period 1. 6, Subjects who participated in a clinical trial and was administered study drug. 7, Subjects with history of alcohol and/or drug abuse. 8, Subjects who was judged not appropriate for this study by study physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24 hour intragastric pH and pharmacokinetics after administration of famotidine. | — |
Countries
Japan
Contacts
Public ContactMasanari Shiramoto
Medical Co. LTA Hakata Clinic Clinical Pharmacology Department
Outcome results
None listed